172 related articles for article (PubMed ID: 25052874)
21. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
[TBL] [Abstract][Full Text] [Related]
22. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.
Cheah CY; Chihara D; Ahmed M; Davis RE; Nastoupil LJ; Phansalkar K; Hagemeister FB; Fayad LE; Westin JR; Oki Y; Fanale MA; Romaguera JE; Wang ML; Lee H; Turturro F; Samaniego F; Rodriguez MA; Neelapu SS; Fowler NH
Ann Oncol; 2016 May; 27(5):895-901. PubMed ID: 26802151
[TBL] [Abstract][Full Text] [Related]
23. FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.
Pisani F; Maini CL; Sciuto R; Dessanti L; D'Andrea M; Assisi D; Petti MC
J Exp Clin Cancer Res; 2011 Feb; 30(1):16. PubMed ID: 21303501
[TBL] [Abstract][Full Text] [Related]
24. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
[TBL] [Abstract][Full Text] [Related]
25. A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era.
Lim RMH; Chan NPX; Khoo LP; Cheng CL; Tan L; Poon EYL; Somasundaram N; Farid M; Tang TPL; Tao M; Lim ST; Chan JY
Sci Rep; 2020 Mar; 10(1):4373. PubMed ID: 32152442
[TBL] [Abstract][Full Text] [Related]
26. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W
Ann Hematol; 2000 Sep; 79(9):493-500. PubMed ID: 11043420
[TBL] [Abstract][Full Text] [Related]
27. Transformed follicular lymphoma (tFL): consolidation therapy may improve survival.
Elhassadi E; Flavin R; Browne P; Conneally E; Hayden P; Quinn F; Higgins E; Vandenberghe E
Ir J Med Sci; 2017 Aug; 186(3):589-595. PubMed ID: 28321641
[TBL] [Abstract][Full Text] [Related]
28. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.
Binkley MS; Brady JL; Hajj C; Chelius M; Chau K; Balogh A; Levis M; Filippi AR; Jones M; Ahmed S; MacManus M; Wirth A; Oguchi M; Vistisen AK; Andraos TY; Ng AK; Aleman BMP; Choi SH; Kirova YM; Hardy S; Reinartz G; Eich HT; Bratman SV; Constine LS; Suh CO; Dabaja B; El-Galaly TC; Hodgson DC; Ricardi U; Yahalom J; Mikhaeel NG; Hoppe RT
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):522-529. PubMed ID: 30858143
[TBL] [Abstract][Full Text] [Related]
29. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study.
Junlén HR; Peterson S; Kimby E; Lockmer S; Lindén O; Nilsson-Ehle H; Erlanson M; Hagberg H; Rådlund A; Hagberg O; Wahlin BE
Leukemia; 2015 Mar; 29(3):668-76. PubMed ID: 25151959
[TBL] [Abstract][Full Text] [Related]
30. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.
Tan D; Horning SJ; Hoppe RT; Levy R; Rosenberg SA; Sigal BM; Warnke RA; Natkunam Y; Han SS; Yuen A; Plevritis SK; Advani RH
Blood; 2013 Aug; 122(6):981-7. PubMed ID: 23777769
[TBL] [Abstract][Full Text] [Related]
31. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party.
El-Najjar I; Boumendil A; Luan JJ; Bouabdallah R; Thomson K; Mohty M; Colombat P; Biron P; Tilly H; Pfreundschuh M; Cordonnier C; Sureda A; Cahn JY; Vernant JP; Gribben J; Cook G; Haynes AP; Ferrant A; Finel H; Montoto S; Dreger P;
Ann Oncol; 2014 Nov; 25(11):2224-2229. PubMed ID: 25193988
[TBL] [Abstract][Full Text] [Related]
32. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
33. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
Sacchi S; Pozzi S; Marcheselli L; Bari A; Luminari S; Angrilli F; Merli F; Vallisa D; Baldini L; Brugiatelli M;
Cancer; 2007 May; 109(10):2077-82. PubMed ID: 17394190
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
35. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
Villa D; Crump M; Panzarella T; Savage KJ; Toze CL; Stewart DA; MacDonald DA; Buckstein R; Lee C; Alzahrani M; Rubinger M; Foley R; Xenocostas A; Sabloff M; Muccilli A; Chua N; Couture F; Larouche JF; Cohen S; Connors JM; Ambler K; Al-Tourah A; Ramadan KM; Kuruvilla J
J Clin Oncol; 2013 Mar; 31(9):1164-71. PubMed ID: 23401459
[TBL] [Abstract][Full Text] [Related]
36. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
37. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.
Phipps C; Gopal AK; Storer BE; Cassaday RD; Press OW; Till BG; Pagel JM; Palanca-Wessels MC; Philip M; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Chauncey T; Maloney DG; Libby EN
Leuk Lymphoma; 2015 Jan; 56(1):92-6. PubMed ID: 24707941
[TBL] [Abstract][Full Text] [Related]
38. Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status.
Behdad A; Boddy CS; Fought AJ; Taxter T; Falkiewicz MK; Ayers E; Chen QC; Chen YH; Karmali R; Pro B; Winter JN; Landsburg DJ; Gordon LI; Kaplan JB
Leuk Lymphoma; 2019 Dec; 60(13):3266-3271. PubMed ID: 31225766
[TBL] [Abstract][Full Text] [Related]
39. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
40. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.
Mozessohn L; Cheung MC; Crump M; Buckstein R; Berinstein N; Imrie K; Kuruvilla J; Piliotis E; Kukreti V
Leuk Lymphoma; 2014 Nov; 55(11):2502-7. PubMed ID: 24450580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
